C
11.99
2.89 (31.72%)
| Previous Close | 9.10 |
| Open | 9.99 |
| Volume | 21,653,646 |
| Avg. Volume (3M) | 903,292 |
| Market Cap | 423,561,152 |
| Price / Sales | 23.87 |
| Price / Book | 60.20 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2024 - 18 Nov 2024 |
| Profit Margin | -102.93% |
| Operating Margin (TTM) | -291.86% |
| Diluted EPS (TTM) | -0.890 |
| Quarterly Revenue Growth (YOY) | 1.40% |
| Total Debt/Equity (MRQ) | 15.97% |
| Current Ratio (MRQ) | 1.37 |
| Return on Assets (TTM) | -44.49% |
| Return on Equity (TTM) | -392.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Capricor Therapeutics, Inc. | Bullish | Mixed |
Stockmoo Score
1.0
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 8.18% |
| % Held by Institutions | 28.47% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 43.00 (Oppenheimer, 258.75%) | Buy |
| Median | 32.50 (171.15%) | |
| Low | 8.00 (Cantor Fitzgerald, -33.26%) | Buy |
| Average | 29.00 (141.95%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 10.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Oct 2024 | 40.00 (233.72%) | Buy | 18.09 |
| 24 Sep 2024 | 40.00 (233.72%) | Buy | 9.10 | |
| Maxim Group | 25 Sep 2024 | 25.00 (108.57%) | Buy | 10.34 |
| 17 Sep 2024 | 12.00 (0.12%) | Buy | 5.08 | |
| Oppenheimer | 25 Sep 2024 | 43.00 (258.75%) | Buy | 10.34 |
| 23 Sep 2024 | 15.00 (25.14%) | Buy | 5.97 | |
| Cantor Fitzgerald | 20 Sep 2024 | 8.00 (-33.26%) | Buy | 5.05 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |